AstraZeneca Reports Results from the P-III (SUPERNOVA) Study of Sipavibart to Prevent COVID-19 in Immunocompromised Patients
Shots: The P-III (SUPERNOVA) study investigates the safety & efficacy of sipav...
Shots: The P-III (SUPERNOVA) study investigates the safety & efficacy of sipav...
Shots: Agreement grants co-exclusive rights to Sanofi to co-commercialize Novavax&...
Shots: The P-II/III (SCORPIO-SR) trial evaluates Ensitrelvir (125/250mg) vs PBO in...
Shots: The 2nd P-III study evaluating safety & efficacy of VV116 (mindeudesivi...
Shots: The US FDA approved P-II IND evaluating silmitasertib (CX-4945) that aimed...
Shots: The European Patent Office declared that Moderna's mRNA patent was inva...
Incisive News in 3 Shots.